JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

Search

Lantheus Holdings Inc

Open

SectorGezondheidszorg

71.78 -0.5

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

71.61

Max

72.53

Belangrijke statistieken

By Trading Economics

Inkomsten

85M

73M

Verkoop

-18M

373M

K/W

Sectorgemiddelde

20.388

38.156

Winstmarge

19.569

Werknemers

808

EBITDA

93M

115M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+121.89% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-2.5B

5B

Vorige openingsprijs

72.28

Vorige sluitingsprijs

71.78

Nieuwssentiment

By Acuity

67%

33%

341 / 375 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Lantheus Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jul 2025, 23:57 UTC

Acquisities, Fusies, Overnames

EQT: To Spend Y407.82B for Tender Offer

29 jul 2025, 23:56 UTC

Acquisities, Fusies, Overnames

EQT: Tender Offer Price Is Y5,700 a Share

29 jul 2025, 23:54 UTC

Acquisities, Fusies, Overnames

EQT To Start Tender Offer for Fujitec

29 jul 2025, 23:50 UTC

Marktinformatie

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 jul 2025, 23:36 UTC

Marktinformatie

Gold Steady Ahead of FOMC Decision -- Market Talk

29 jul 2025, 22:57 UTC

Marktinformatie

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 jul 2025, 22:50 UTC

Marktinformatie

Mondelez Warns of Price Increases in North America -- Market Talk

29 jul 2025, 22:44 UTC

Acquisities, Fusies, Overnames

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 jul 2025, 22:41 UTC

Acquisities, Fusies, Overnames

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 jul 2025, 22:41 UTC

Acquisities, Fusies, Overnames

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 jul 2025, 22:35 UTC

Winsten

IGO Maintains Nova Life of Mine Production Guidance

29 jul 2025, 22:35 UTC

Winsten

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 jul 2025, 22:35 UTC

Winsten

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 jul 2025, 22:34 UTC

Winsten

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 jul 2025, 22:34 UTC

Winsten

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 jul 2025, 22:34 UTC

Marktinformatie
Winsten

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 jul 2025, 22:33 UTC

Winsten

IGO Had A$279.7 Million of Cash at End-June

29 jul 2025, 22:33 UTC

Winsten

IGO 4Q Underlying Free Cash A$2.4 Million

29 jul 2025, 22:33 UTC

Winsten

IGO FY Sales Revenue A$512.5 Million

29 jul 2025, 22:33 UTC

Winsten

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 jul 2025, 22:32 UTC

Winsten

IGO FY Nickel Production 17,173 Tons

29 jul 2025, 22:32 UTC

Winsten

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 jul 2025, 22:32 UTC

Winsten

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 jul 2025, 22:31 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

29 jul 2025, 22:31 UTC

Marktinformatie
Winsten

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 jul 2025, 22:31 UTC

Winsten

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 jul 2025, 22:31 UTC

Winsten

IGO FY Spodumene Production 1.48 Million Tons

29 jul 2025, 22:30 UTC

Winsten

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 jul 2025, 22:30 UTC

Winsten

IGO 4Q Underlying Ebitda A$62 Million

29 jul 2025, 22:22 UTC

Winsten

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Peer Vergelijking

Prijswijziging

Lantheus Holdings Inc Prognose

Koersdoel

By TipRanks

121.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 160.67 USD  121.89%

Hoogste 355 USD

Laagste 109 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lantheus Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technische score

By Trading Central

79.24 / 103.64Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

341 / 375 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.